Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.37 |
| ▸ | RXRA | P19793 | 5/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 3/20 | 0.34 |
| ▸ | FNTB | P49356 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12175568 | 0.86 | POLB (0.41) | JAK2JAK1ACACBFNTAFNTB | |
| SCHEMBL14650767 | 0.79 | PRCP (0.51) | JAK2JAK1NR1H2GRM5 | |
| SCHEMBL14650760 | 0.78 | POLB (0.44) | JAK2JAK1ACACBFNTAFNTB | |
| SCHEMBL30623411 | 0.73 | GRM5 (0.37) | JAK2JAK1NR1H2RXRANR1H3 | |
| SCHEMBL14650761 | 0.71 | KDM1A (0.43) | JAK2JAK1NR1H2RXRANR1H3 | |
| SCHEMBL14650759 | 0.69 | STS (0.42) | HDAC1STS | |
| SCHEMBL14650758 | 0.69 | PRCP (0.53) | JAK2JAK1NR1H2RXRANR1H3 | |
| SCHEMBL18616707 | 0.69 | GRM5 (0.44) | JAK2JAK1NR1H2RXRANR1H3 | |
| SCHEMBL30623236 | 0.69 | ACACB (0.34) | JAK2JAK1ACACBNR1H2RXRA | |
| SCHEMBL13858221 | 0.68 | POLB (0.47) | JAK2JAK1ACACBEIF2AK4STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785634-B2 | Spiropiperidine prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785634-B2 | Spiropiperidine prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-01-24 | — | — | US | disclosed |
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023515-A1 | NOVEL SPIROPIPERIDINE PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, PEPD | JAK2 3310/4885JAK1 4624/4885ACACB 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.